Connect Biopharma Reports Positive Phase 2 Data for COPD Treatment Rademikibart

Connect Biopharma (CNTB) announced positive topline results from its global Phase 2 study of rademikibart, an antibody treatment for acute exacerbations in adults with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. The study successfully met its primary endpoint, demonstrating a significant reduction in treatment failure compared to placebo.

Key Details

• Primary Endpoint Met: Rademikibart significantly reduced the rate of treatment failure by 81% through Week 4 compared to placebo (p=0.0122).
• Significant Reductions: The treatment also reduced the rate of new moderate-to-severe COPD exacerbations by 85% and new hospitalizations or emergency department visits for exacerbations by 100% through Week 4.
• Next Steps: Based on these results, Connect Biopharma plans to engage with the U.S. Food and Drug Administration (FDA) to discuss a Phase 3 registrational program for rademikibart.